Analysts Issue Forecasts for TScan Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:TCRX)

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Analysts at Lifesci Capital decreased their FY2024 earnings estimates for TScan Therapeutics in a research note issued to investors on Monday, May 13th. Lifesci Capital analyst S. Slutsky now forecasts that the company will earn ($1.02) per share for the year, down from their previous estimate of ($0.97). The consensus estimate for TScan Therapeutics' current full-year earnings is ($1.01) per share. Lifesci Capital also issued estimates for TScan Therapeutics' Q4 2024 earnings at ($0.24) EPS.

Several other research firms have also commented on TCRX. Needham & Company LLC reissued a "buy" rating and issued a $11.00 target price on shares of TScan Therapeutics in a report on Monday. Wedbush restated an "outperform" rating and set a $10.00 price target on shares of TScan Therapeutics in a report on Monday. HC Wainwright reiterated a "buy" rating and issued a $15.00 price objective on shares of TScan Therapeutics in a report on Tuesday. Finally, BTIG Research started coverage on shares of TScan Therapeutics in a research report on Thursday. They issued a "buy" rating and a $12.00 price target for the company. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $12.00.

TScan Therapeutics Stock Performance

Shares of TScan Therapeutics stock traded down $0.03 during trading on Thursday, reaching $8.90. The company's stock had a trading volume of 174,774 shares, compared to its average volume of 184,859. The firm has a market cap of $426.13 million, a PE ratio of -6.98 and a beta of 0.91. TScan Therapeutics has a 52 week low of $1.93 and a 52 week high of $9.36. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.18. The business's 50-day moving average price is $7.55 and its 200-day moving average price is $6.28.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last posted its earnings results on Wednesday, March 6th. The company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.08. The business had revenue of $7.21 million for the quarter, compared to analyst estimates of $2.94 million. TScan Therapeutics had a negative return on equity of 56.89% and a negative net margin of 653.50%.

Institutional Investors Weigh In On TScan Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. abrdn plc bought a new stake in TScan Therapeutics in the 4th quarter worth about $1,166,000. Pale Fire Capital SE purchased a new stake in TScan Therapeutics during the third quarter worth about $42,000. Letko Brosseau & Associates Inc. bought a new position in TScan Therapeutics during the third quarter valued at $83,000. Vanguard Group Inc. lifted its position in shares of TScan Therapeutics by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 1,808,152 shares of the company's stock valued at $14,357,000 after buying an additional 20,000 shares during the last quarter. Finally, Tocqueville Asset Management L.P. bought a new position in TScan Therapeutics in the 1st quarter worth about $1,685,000. 82.83% of the stock is owned by hedge funds and other institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.